Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026.

Wanbury Limited Regd. Office: BSEL Tech Park, B-Wing, 10th Floor, Sector-30A, Opp. Vashi Railway Station, Vashi, Navi Mumbai 400703 Maharashtra, INDIA Tel: +91-22-6794 2222 +91-22-7196 3222 CIN: L51900MH1988PLC048455 Email: info@wanbury.com Website: www.wanbury.com November 6, 2026 To To BSE Limited National Stock Exchange of India Ltd, PJ. Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street Bandra (East), Mumbai-400 001. Mumbai - 400 051. Script Code: 524212 Script Code: WANBURY Sub.: Press release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026 As per Regulation 30 of LODR, please find attached herewith copy of press release on Standalone and Consolidated Un-audited Financial Results (UFR) for the second quarter and half year ended 30th September, 2026. This is for your information and record. Thanking you. Yours faithfully, For Wanbury Limited Jitendra J. Gandhi Company Secretary Encl.: a/a. PRESS RELEASE 6th November, 2026, Mumbai: Wanbury Limited, a pharmaceutical company with a presence in the global API market and domestic branded formulations, has announced its financial results for the second quarter and half year ended 30th September 2026. Financial Highlights Particulars (Rs. Cr) Q2 FY27 Q2 FY26 Y-o-Y Q1 FY27 Q-o-Q Revenue from Operations 182.9 160.1 14.3% 165.6 10.5% Other Income 0.1 0.2 - 0.4 - EBITDA* 26.2 26.0 0.9% 16.6 57.9% EBITDA Margin (%) 14.3% 16.2% (190) bps 10.0% 431 bps PAT 11.9 15.2 (21.7%) 3.2 266.4% PAT Margin (%) 6.5% 9.5% (299) bps 2.0% 454 bps *Includes Other Income Particulars (Rs. Cr) H1 FY27 H1 FY26 Y-o-Y Revenue from Operations 348.5 323.2 7.8% Other Income 0.5 0.6 - EBITDA* 42.8 50.8 (15.7%) EBITDA Margin (%) 12.3% 15.7% (342) bps PAT 15.1 28.7 (47.2%) PAT Margin (%) 4.3% 8.9% (453) bps *Includes Other Income For the quarter ended September 30, 2026 • Revenue from Operations stood at Rs. 182.9 crore, compared to Rs. 160.1 crore in Q2 FY26, registering a growth of 14.3% YoY, and Rs. 165.6 crore in Q1 FY27, a growth of 10.5% QoQ. The quarter marked a recovery in Revenue and Profitability from the disruption caused by the crisis in West Asia in Q1 FY27. • Gross profit stood at Rs. 99.1 crore, compared to Rs. 93.2 crore in Q2 FY26 and Rs. 86.9 crore in Q1 FY27. Gross margin improved to 54.2% from 52.5% in Q1 FY27, as a substantial part of the increase in input costs was passed on to customers during the quarter. Gross margin remained below the 58.2% recorded in Q2 FY26, as prices of solvents and other crude oil linked raw materials continued to remain elevated in the aftermath of the West Asia crisis. The balance of the cost increase is expected to be passed on in the coming quarter. • EBITDA (including other income) stood at Rs. 26.2 crore, compared to Rs. 26.0 crore in Q2 FY26 and Rs. 16.6 crore in Q1 FY27, registering a growth of 57.9% QoQ. EBITDA margin improved to 14.3% from 10.0% in Q1 FY27, against 16.2% in Q2 FY26. • Finance costs reduced to Rs. 6.3 crore, from Rs. 8.0 crore in Q1 FY27 and Rs. 7.1 crore in Q2 FY26, reflecting the refinancing of borrowings at a lower interest rate effective 1st July 2026. • Profit before tax stood at Rs. 15.7 crore, compared to Rs. 15.2 crore in Q2 FY26 and Rs. 4.6 crore in Q1 FY27, registering a growth of 3.7% YoY. • PAT stood at Rs. 11.9 crore, compared to Rs. 15.2 crore in Q2 FY26 and Rs. 3.2 crore in Q1 FY27, with EPS of Rs. 3.40 as against Rs. 4.58 in Q2 FY26 and Rs. 0.93 in Q1 FY27. The YoY decline in PAT is on account of provision for deferred tax liabilities created, beginning FY27. • For H1 FY27, Revenue from Operations stood at Rs. 348.5 crore, a growth of 7.8% over H1 FY26, with EBITDA of Rs. 42.8 crore and PAT of Rs. 15.1 crore. Net cash generated from operating activities stood at Rs. 37.5 crore in H1 FY27, against net cash used of Rs. 5.7 crore in H1 FY26. • The Company has presented consolidated financial results for this quarter, following the incorporation of Wanbury Skin Health Limited, an 82% subsidiary, during the quarter. On a consolidated basis, Revenue from Operations stood at Rs. 182.9 crore, EBITDA at Rs. 22.9 crore and PAT at Rs. 8.5 crore for Q2 FY27, after absorbing a loss of Rs. 3.4 crore in the subsidiary on expenses incurred ahead of its commercial launch in October 2026. Business Highlights • The Company will resume dispatches of Ketamine HCl (anaesthetic) API in the current quarter, following the completion of various subject matter expert regulatory audits, with the first dispatches planned in November 2026 itself. • The Company is expanding its API portfolio by validating new products, including Quetiapine Fumarate, Sitagliptin and Empagliflozin, with regulatory filings planned in the coming quarters. These APIs are expected to be available for sale in semi-regulated markets in the interim period. • During July and August 2026, the Company received nine “No DMF Deficiency” letters from the USFDA for its Metformin HCl Drug Master File, issued as part of the USFDA’s review of ANDAs filed by the Company’s customers. In the same period, the Company also received “No DMF Deficiency” letters for Paroxetine HCl and Diphenhydramine HCl, opening up new business opportunities with customers in the regulated US market. • The Company received approval from the European Directorate for the Quality of Medicines and Healthcare (EDQM) for its new product, Rivaroxaban API, in the form of a Certificate of Suitability (CEP). This will enable the Company to meet customer demand in the EU and other markets accepting CEP. • The Company’s API manufacturing site at Tanuku, Andhra Pradesh received the GMP Compliance Certificate from Australia’s Therapeutic Goods Administration (TGA) on 28th October 2026, following an inspection conducted on 8th and 9th June 2026. The certificate covers six APIs: Metformin HCl, Tramadol HCl, Sertraline HCl, Diphenhydramine HCl, Mefenamic Acid and Paroxetine HCl Hemihydrate, and is valid until 9th December 2028. The TGA will now proceed with issuing GMP clearances to Australian sponsors, enabling supply of the approved APIs to the Australian market. • The Company commercialised a new Metformin DC (directly compressible) business in Saudi Arabia, with an annual revenue potential of about Rs. 10 crore. In Mexico, the Company’s customer won a two-year tender for the supply of Metformin, valued at approximately Rs. 15 crore per annum. • The new manufacturing block at the Andhra Pradesh site remains under validation for new APIs. The Company expects progress on new product launches towards the end of the current financial year, which will reflect in performance in the coming year, and continues to strengthen the pipeline of products under evaluation for commercialisation. • The Patalganga facility received the “Certificate of Excellence” from the National Safety Council for safety performance for the third consecutive year, and the Tanuku facility received the “Best Employer Award” from the Government of Andhra Pradesh in recognition of its employee practices and workplace culture. • Wanbury Skin Health Limited, a subsidiary incorporated during the quarter, launched its berrysoft™ baby product range across multiple states in India in October 2026, marking the Company’s entry into the paediatric dermatology segment. The range comprises Gentle Bathing Bar, Gentle Body Wash, Foam Shampoo and Syndet Handwash, with Moisturising Lotion, Diaper Rash Cream and Moisturising Cream in the pipeline. The subsidiary has received GST registration in five states and CFA drug licences in Mumbai, Jaipur, Patna and Ambala, and will leverage the Company’s existing relationships with paediatricians, where it already markets its cough and cold products. Commenting on the performance, Mr. Mohan Rayana, Director of Wanbury Limited, said, “Q2 FY27 marks a recovery from the disruption caused by the West Asia crisis in the previous quarter. Revenue from Operations grew 10.5% sequential [Showing first 8,000 characters — download PDF for full document]